Publication:
BRAFV600E, BANCR, miR-203a-3p and miR-204-3p in Risk Stratification of PTC Patients

dc.contributor.authorStojanović, Stefana (57219097598)
dc.contributor.authorŠelemetjev, Sonja (24463032600)
dc.contributor.authorĐorić, Ilona (57219769876)
dc.contributor.authorJanković Miljuš, Jelena (55555671900)
dc.contributor.authorTatić, Svetislav (6701763955)
dc.contributor.authorŽivaljević, Vladan (6701787012)
dc.contributor.authorIšić Denčić, Tijana (13008078500)
dc.date.accessioned2025-06-12T11:51:49Z
dc.date.available2025-06-12T11:51:49Z
dc.date.issued2023
dc.description.abstractIn order to enhance the risk stratification of papillary thyroid carcinoma (PTC) patients, we assessed the presence of the most common mutation in PTC (BRAFV600E) with the expression profiles of long non-coding RNA activated by BRAFV600E (BANCR) and microRNAs, which share complementarity with BANCR (miR-203a-3p and miR-204-3p), and thereafter correlated it with several clinicopathological features of PTC. BRAFV600E was detected by mutant allele-specific PCR amplification. BANCR and miRs levels were determined by quantitative RT-PCR. Bioinformatic analysis was applied to determine the miRs’ targets. The expression profile of miR-203a-3p/204-3p in PTC was not affected by BRAFV600E. In the BRAFV600E-positive PTC, high expression of miR-203a-3p correlated with extrathyroidal invasion (Ei), but the patients with both high miR-203a-3p and upregulated BANCR were not at risk of Ei. In the BRAFV600E-negative PTC, low expression of miR-204-3p correlated with Ei, intraglandular dissemination and pT status (p < 0.05), and the mutual presence of low miR-204-3p and upregulated BANCR increased the occurrence of Ei. Bioinformatic analysis predicted complementary binding between miR-203a-3p/204-3p and BANCR. The co-occurrence of tested factors might influence the spreading of PTC. These findings partially describe the complicated network of interactions that may occur during the development of PTC aggressiveness, potentially providing a new approach for high-risk PTC patient selection. © 2023 by the authors.
dc.identifier.urihttps://doi.org/10.3390/biomedicines11123338
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85180671200&doi=10.3390%2fbiomedicines11123338&partnerID=40&md5=73604ec34259e0e68c469663b35c26c7
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/1577
dc.subjectaggressiveness
dc.subjectlong non-coding RNA
dc.subjectmicroRNAs
dc.subjectpapillary thyroid carcinoma
dc.subjectprognosis
dc.subjecttumor markers
dc.titleBRAFV600E, BANCR, miR-203a-3p and miR-204-3p in Risk Stratification of PTC Patients
dspace.entity.typePublication

Files